CANCER resistance surveillance program: initial results from hematology-oncology centers in North America. Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance (Q44263661)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	CANCER resistance surveillance program: initial results from hematology-oncology centers in North America. Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 December 2017

CANCER resistance surveillance program: initial results from hematology-oncology centers in North America. Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance (English)

1 reference

Europe PubMed Central

1 December 2017

1 reference

based on heuristic

inferred from title

3

object named as

Ronald N Jones

1 reference

Europe PubMed Central

1 December 2017

author name string

Alan H Mutnick

1

1 reference

Europe PubMed Central

1 December 2017

Jeffrey T Kirby

2

1 reference

Europe PubMed Central

1 December 2017

CANCER Study Group

4

1 reference

Europe PubMed Central

1 December 2017

language of work or name

0 references

publication date

1 January 2003

1 reference

Europe PubMed Central

1 December 2017

Annals of Pharmacotherapy

1 reference

Europe PubMed Central

1 December 2017

37

1 reference

Europe PubMed Central

1 December 2017

47-56

1 reference

Europe PubMed Central

1 December 2017

1

1 reference

Europe PubMed Central

1 December 2017

Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Empirical therapy of febrile neutropenic patients with mucositis: challenge of risk-based therapy

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Surveillance of antimicrobial resistance--what, how and whither?

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Infections caused by viridans streptococci in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Vancomycin susceptibility of oxacillin-resistant Staphylococcus aureus isolates causing nosocomial bloodstream infections

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Hospital-acquired infections: diseases with increasingly limited therapies

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Prevalence of beta-lactamases among 1,072 clinical strains of Proteus mirabilis: a 2-year survey in a French hospital

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Extended-spectrum beta-lactamase in Proteus mirabilis.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Persistent fever in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1C292

21 January 2018

Identifiers

10.1345/APH.1C292

1 reference

Europe PubMed Central

1 December 2017

1 reference

Europe PubMed Central

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44263661&oldid=2108985502"